Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Bayer
- 12 Apr 2018 Planned End Date changed from 30 Nov 2019 to 28 Feb 2020.
- 12 Apr 2018 Planned primary completion date changed from 30 Sep 2019 to 31 Dec 2019.
- 12 Apr 2018 Planned initiation date changed from 31 Mar 2018 to 30 Jun 2018.